Komori
Share Issuance and Disposal4884Kringle Pharma,Inc.Pharmaceuticals

Notice Regarding a Reduction in the Amounts of Capital and Capital Reserve and the Disposal of Surplus

The Company will reduce stated capital by ¥331,330,050 and capital reserve by ¥1,341,379,151, and transfer the total amount of ¥1,672,709,201 to other capital surplus. The entire amount will then be transferred to retained earnings to offset the deficit in retained earnings.

Worth reading
27Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1672709201
¥
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

発行済株式総数

No change

Procedures under the Corporate Code of Conduct
Subject to approval at the Extraordinary General Meeting of Shareholders
Impact on Business Performance
No impact on business results
Details of issuance or disposal
ItemDetails
Total number of issued sharesNo change
Procedures under the Corporate Code of ConductSubject to approval at the Extraordinary General Meeting of Shareholders
Impact on Business PerformanceNo impact on business results
Items this document does not state (25)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The purpose is to strengthen the Company's financial position, increase flexibility in future capital policies, including shareholder returns, reduce the tax burden, and offset the deficit in retained earnings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Reduction in the Amounts of Capital and Capital Reserve and the Disposal of Surplus | Kringle Pharma,Inc. (4884) timely disclosure | Komori